MARKET

REPH

REPH

Recro Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.10
+0.59
+3.57%
After Hours: 17.10 0 0.00% 16:00 11/15 EST
OPEN
16.68
PREV CLOSE
16.51
HIGH
17.36
LOW
16.45
VOLUME
427.77K
TURNOVER
--
52 WEEK HIGH
18.20
52 WEEK LOW
5.53
MARKET CAP
388.69M
P/E (TTM)
-7.3381
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of REPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

REPH News

  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.3d ago
  • Edited Transcript of REPH earnings conference call or presentation 8-Nov-19 1:00pm GMT
  • Thomson Reuters StreetEvents.3d ago
  • Recro Pharma Announces Effectiveness of Baudax Bio Form 10 Registration Statement
  • GlobeNewswire.4d ago
  • Recro Pharma, Inc. (REPH) CEO Gerri Henwood on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/10 06:34

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About REPH

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
More

Webull offers Recro Pharma Inc (REPH) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.